Biomarin Pharmaceutical Inc. BMRN

NAS: BMRN | ISIN: US09061G1013   18/03/2026
55,43 USD (-1,11%)
(-1,11%)   18/03/2026

12 maart 2026 · BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

28 februari 2026 · U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) · Persbericht

24 februari 2026 · BioMarin to Participate in Four Upcoming Investor Conferences in March · Persbericht

23 februari 2026 · BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results · Persbericht

17 februari 2026 · BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET · Persbericht

12 februari 2026 · BioMarin Announces Closing of Private Offering of Senior Notes · Persbericht

29 januari 2026 · BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility · Persbericht

26 januari 2026 · BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility · Persbericht

12 januari 2026 · BioMarin Appoints Arpit Davé Chief Digital and Information Officer · Persbericht

9 januari 2026 · Veeva et BioMarin forment un partenariat stratégique à long terme · Persbericht

8 januari 2026 · BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA · Persbericht

8 januari 2026 · Veeva and BioMarin Form Long-Term Strategic Partnership · Persbericht

19 december 2025 · BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook · Persbericht

11 november 2025 · BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England · Persbericht

29 oktober 2025 · FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria · Persbericht

27 oktober 2025 · BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update · Persbericht

22 oktober 2025 · BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET · Persbericht

8 september 2025 · BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting · Persbericht

6 september 2025 · BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism · Persbericht

27 augustus 2025 · BioMarin to Participate in Upcoming Investor Conferences · Persbericht

Mijn selecties